HRTX Heron Therapeutics
- 3.265
- +0.015+0.46%
Heron Therapeutics News
Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.Zynrelef will be included under Medicare's Outpatient
Express News | Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And...
Express News | Heron Therapeutics Announces the Inclusion of Zynrelef® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the Opps and the Asc Payment System
Breakeven On The Horizon For Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Heron Therapeutics, Inc., a commercial-stage
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics Down Over 19%, On Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Heron Therapeutics Inc.(HRTX) is currently at $2.79, down $0.68 or 19.62% --Would be lowest close since May 10, 2024, when it closed at $2.77 --On pace for largest percent decrease since May 12, 202
Express News | Heron Therapeutics Shares Are Trading Lower. The FDA Acknowledged the Receipt of the Company's Prior Approval Supplement Application for ZYNRELEF
Heron Therapeutics' ZYNRELEF Review Date Set by FDA
Express News | Heron Therapeutics Inc - U.S. Food and Drug Administration ("FDA") Assigned a Prescription Drug User Fee Act ("Pdufa") Goal Date of September 23, 2024
Express News | Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle ("Van")
Despite Shrinking by US$52m in the Past Week, Heron Therapeutics (NASDAQ:HRTX) Shareholders Are Still up 181% Over 1 Year
When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Heron The
Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Heron Therapeutics With Buy Rating, Announces Price Target of $7
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 89.19% Rodman & Renshaw → $7 Initiates Coverage On → Buy 05/16/2024 35.14% Needham $5 → $5 Reit
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Rodman & Renshaw Initiates Heron Therapeutics(HRTX.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Heron Therapeutics(HRTX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Northland Securities analyst Carl Byrnes maintains $Heron Therapeutics(HRTX.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 3
Analysis
Price Target
No Data
